免疫球蛋白转录因子2在卵巢癌中的表达及临床意义

Expression of ITF2 in ovarian cancer and its clinical significance

目的:探讨免疫球蛋白转录因子2(ITF2)在卵巢癌中的表达及临床意义。方法:免疫组化法检测20例卵巢良性囊腺瘤、20例卵巢交界性囊腺瘤、40例卵巢恶性肿瘤中ITF2表达水平,并分析其表达量与临床病理参数之间的关系。选取卵巢癌细胞株SKOV3、HO8910及永生化卵巢上皮细胞IOSE80,Western blot法检测细胞中ITF2表达水平,划痕实验检测卵巢癌细胞的转移能力。结果:卵巢癌与交界性肿瘤中ITF2蛋白阳性表达率明显高于卵巢良性囊腺瘤(55.0%、45.0%vs 25.0%,P<0.05)。卵巢癌中ITF2表达水平与病理分级、FIGO分期有关(P<0.05)。卵巢癌细胞株SKOV3与HO8910中ITF2表达量高于正常卵巢上皮细胞IOSE80,ITF2表达量更高的SKOV3细胞的转移能力明显高于HO8910细胞(P<0.05)。结论:ITF2在卵巢癌组织中多呈高表达,且与肿瘤转移能力相关。提示ITF2蛋白可能参与卵巢癌的发生和发展,有望成为卵巢癌诊断与治疗的一个潜在生物学标记。

Objective:To investigate the expression level and clinical significance of immunoglobulin transcription factor 2(ITF2)in ovarian cancer.M ethods:Immunohistochemistry was used to detect the expression of ITF2 in 20 cases of ovarian benign cystadenomas,20 cases of borderline cystadenomas and 40 cases of ovarian cancer.The association of the expression of ITF2 protein with clinicopathological characteristics of ovarian cancer was analyzed.The expressions of ITF2 in ovarian cancer cell lines SKOV3 and HO8910 and immortalized ovarian epithelial cell IOSE80 were detected by Western blot,and the motility of cancer cells was determined by wound healing assay.Results:The expression of ITF2 protein in ovarian cancer and borderline tumor was significantly higher than that in benign ovarian cystadenoma(P<0.05),and the positive rates were 55.0%,45.0%and 25.0%,respectively.The expression of ITF2 was associated with histologic grade and FIGO stage of ovarian cancer(P<0.05).ITF2 expression in ovarian cancer cell line SKOV3 or HO8910 was higher than that in normal ovarian epithelial cell line IOSE80.Cytological experiments confirmed that SKOV3 cells with more ITF2 expression had significantly higher metastasis potential than that of HO8910 cells(P<0.05).C onclusion:ITF2 overexpression in ovarian cancer and associate with tumor metastasis potential.The ITF2 protein may be involved in the occurrence and development of ovarian cancer,and may be an effective indicator for the diagnosis and treatment of ovarian cancer.